The global inflammatory bowel disease drugs market was valued at $20,988 million in 2021 and is projected to reach $34.513.56 million by 2031 registering a CAGR of 5.1% from 2022 to 2031.
Inflammatory bowel disease is a group of disorders that causes chronic inflammation in the intestine and it is a type of gastrointestinal disease. It includes ulcerative colitis and Crohn’s disease, and both these types of diseases effect on digestive system. The prolonged inflammation of these diseases leads to damage of the gastrointestinal tract. The ulcerative colitis causes inflammation to the large intestine in the digestive tract and causes other non-digestive problems. Whereas, Crohn’s disease causes inflammation in any part of the digestive tract and it mainly affects the end part of the small intestine.
The main factors that foster the growth of the inflammatory bowel disease drugs market are alarming increase in number of chronic inflammatory bowel diseases, rise in government initiatives for development of pharmaceutical industry, and increase in number of approvals for ulcerative colitis drugs. In addition, according to the survey conducted by Marc D Basson on Ulcerative Colitis, in 2019, about one million people were affected with UC. Moreover, as per Crohn’s and Colitis Foundation (CCFA), in 2020, around 70,000 cases of inflammatory bowel disease were diagnosed in the U.S. Thus, rise in number of cases of ulcerative colitis disease drives the growth of the market. Furthermore, according to the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), there were around 10 million people suffering from inflammatory bowel disease in 2020 across the world and about 3.4 million in Europe. Furthermore, ECCFA has collaborated with Medscape to conduct training session on biosimilars for the treatment of inflammatory bowel disease. Thus, factors such as rise in prevalence of inflammatory bowel disease and collaboration among private institutions to develop new solutions for the treatment of the diseases propels the growth of the market.
In addition, increase in approval of biosimilars such as Inflectra, Imraldi, and Hyrimoz is expected to rise the adoption of effective treatment. In addition, the presence of other drugs such as IXFI which is launch by Pfizer Inc. and Cyltezo by Boehringer Ingelheim is expected to fuel the growth of the market. For instance, in September 2019, Janssen Biotech Inc. has received an FDA approval for its STELARA (ustekinumab) drug for the treatment of ulcerative colitis. STELARA is the first approved drug for ulcerative colitis which targets interleukin-12 and interleukin-23 cytokines. The interleukin-12 and interleukin-23 cytokines plays an important role in inflammatory and immune disease responses. It provides improvement of the intestinal tract as assessed by a novel histologic endoscopic mucosal improvement endpoint. In addition, in February 2022, Johnson & Johnson has introduced the safety and efficacy of Tremfya drug which is currently approved for the treatment of psoriasis but now it pushes to use for the treatment of Crohn’s and ulcerative colitis. Thus, increase in approval of biologics and biosimilars for the treatment of Crohn’s disease and ulcerative colitis by key players contribute towards the growth of the market.
In Western World, it was reported that there were increase in incidences of inflammatory bowel disease by about 0.6% out of the overall population in Canada. The prevalence of inflammatory bowel disease is increasing rapidly in developed countries. Moreover, in recent years the metagenomics research, bio-information analysis technology has begun to emerge in medical research field which contribute to inflammatory bowel disease treatment research greatly. Thus, rise in new trends in the treatment of inflammatory bowel disease drives the growth of the market. According to the Indian Journal of Medical Research, in 2021, the prevalence of inflammatory bowel disease has increasing due to lack of hygiene. The study shows that around 200 Crohn’s disease patients from Vellore, India. Thus, rise in issues regarding to personal hygiene drives the growth of the market. Moreover, development of pharmaceutical industries and improvement in healthcare spending are anticipated to drive the growth of the inflammatory bowel disease drugs market. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase the demand for treatment of ulcerative colitis drugs. This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the inflammatory bowel disease drugs market.
The cause of inflammatory bowel disease is known to involve an interaction between genes, the immune system, and environmental factors. Smoking is a factor that is consistently associated with inflammatory bowel disease. For instance, according to Indian Journal of Medical Research in 2021, there were 65% prevalence of smoking in Asians. Thus, increase in frequency of smoking increases the risk of ulcerative colitis, which is expected to contribute toward the growth of the inflammatory bowel disease drugs market. However, patent expiry and availability of alternative surgery option for inflammatory bowel disease treatment restrict the market growth. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase demand for treatment of ulcerative colitis drugs and Crohn’s disease drugs .This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the inflammatory bowel disease drugs market.
The inflammatory bowel disease drugs market is studied across type, drug class, and distribution channel. On the basis of type, the market is segmented into ulcerative colitis, and Crohn’s disease. By drug class, the market is fragmented into TNF inhibitors, Corticosteroids, Aminosalicylates, JAK inhibitors, Anti-integrin, IL inhibitors, and others. By distribution channel, it is categorized into hospital pharmacy, retail pharmacy and online pharmacy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players mentioned in the report are AbbVie Inc., Bristol Myers Squibb, Celltrion Healthcare, Eli-Lilly, Johnson & Johnson Services Inc., Merck & Co, Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd., and UCB S.A
Inflammatory bowel disease is a group of disorders that causes chronic inflammation in the intestine and it is a type of gastrointestinal disease. It includes ulcerative colitis and Crohn’s disease, and both these types of diseases effect on digestive system. The prolonged inflammation of these diseases leads to damage of the gastrointestinal tract. The ulcerative colitis causes inflammation to the large intestine in the digestive tract and causes other non-digestive problems. Whereas, Crohn’s disease causes inflammation in any part of the digestive tract and it mainly affects the end part of the small intestine.
The main factors that foster the growth of the inflammatory bowel disease drugs market are alarming increase in number of chronic inflammatory bowel diseases, rise in government initiatives for development of pharmaceutical industry, and increase in number of approvals for ulcerative colitis drugs. In addition, according to the survey conducted by Marc D Basson on Ulcerative Colitis, in 2019, about one million people were affected with UC. Moreover, as per Crohn’s and Colitis Foundation (CCFA), in 2020, around 70,000 cases of inflammatory bowel disease were diagnosed in the U.S. Thus, rise in number of cases of ulcerative colitis disease drives the growth of the market. Furthermore, according to the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), there were around 10 million people suffering from inflammatory bowel disease in 2020 across the world and about 3.4 million in Europe. Furthermore, ECCFA has collaborated with Medscape to conduct training session on biosimilars for the treatment of inflammatory bowel disease. Thus, factors such as rise in prevalence of inflammatory bowel disease and collaboration among private institutions to develop new solutions for the treatment of the diseases propels the growth of the market.
In addition, increase in approval of biosimilars such as Inflectra, Imraldi, and Hyrimoz is expected to rise the adoption of effective treatment. In addition, the presence of other drugs such as IXFI which is launch by Pfizer Inc. and Cyltezo by Boehringer Ingelheim is expected to fuel the growth of the market. For instance, in September 2019, Janssen Biotech Inc. has received an FDA approval for its STELARA (ustekinumab) drug for the treatment of ulcerative colitis. STELARA is the first approved drug for ulcerative colitis which targets interleukin-12 and interleukin-23 cytokines. The interleukin-12 and interleukin-23 cytokines plays an important role in inflammatory and immune disease responses. It provides improvement of the intestinal tract as assessed by a novel histologic endoscopic mucosal improvement endpoint. In addition, in February 2022, Johnson & Johnson has introduced the safety and efficacy of Tremfya drug which is currently approved for the treatment of psoriasis but now it pushes to use for the treatment of Crohn’s and ulcerative colitis. Thus, increase in approval of biologics and biosimilars for the treatment of Crohn’s disease and ulcerative colitis by key players contribute towards the growth of the market.
In Western World, it was reported that there were increase in incidences of inflammatory bowel disease by about 0.6% out of the overall population in Canada. The prevalence of inflammatory bowel disease is increasing rapidly in developed countries. Moreover, in recent years the metagenomics research, bio-information analysis technology has begun to emerge in medical research field which contribute to inflammatory bowel disease treatment research greatly. Thus, rise in new trends in the treatment of inflammatory bowel disease drives the growth of the market. According to the Indian Journal of Medical Research, in 2021, the prevalence of inflammatory bowel disease has increasing due to lack of hygiene. The study shows that around 200 Crohn’s disease patients from Vellore, India. Thus, rise in issues regarding to personal hygiene drives the growth of the market. Moreover, development of pharmaceutical industries and improvement in healthcare spending are anticipated to drive the growth of the inflammatory bowel disease drugs market. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase the demand for treatment of ulcerative colitis drugs. This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the inflammatory bowel disease drugs market.
The cause of inflammatory bowel disease is known to involve an interaction between genes, the immune system, and environmental factors. Smoking is a factor that is consistently associated with inflammatory bowel disease. For instance, according to Indian Journal of Medical Research in 2021, there were 65% prevalence of smoking in Asians. Thus, increase in frequency of smoking increases the risk of ulcerative colitis, which is expected to contribute toward the growth of the inflammatory bowel disease drugs market. However, patent expiry and availability of alternative surgery option for inflammatory bowel disease treatment restrict the market growth. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase demand for treatment of ulcerative colitis drugs and Crohn’s disease drugs .This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the inflammatory bowel disease drugs market.
The inflammatory bowel disease drugs market is studied across type, drug class, and distribution channel. On the basis of type, the market is segmented into ulcerative colitis, and Crohn’s disease. By drug class, the market is fragmented into TNF inhibitors, Corticosteroids, Aminosalicylates, JAK inhibitors, Anti-integrin, IL inhibitors, and others. By distribution channel, it is categorized into hospital pharmacy, retail pharmacy and online pharmacy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players mentioned in the report are AbbVie Inc., Bristol Myers Squibb, Celltrion Healthcare, Eli-Lilly, Johnson & Johnson Services Inc., Merck & Co, Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd., and UCB S.A
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the inflammatory bowel disease drugs market analysis from 2021 to 2031 to identify the prevailing inflammatory bowel disease drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the inflammatory bowel disease drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global inflammatory bowel disease drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Ulcerative Colitis
- Crohns Disease
By Drug Class
- TNF inhibitors
- Corticosteroids
- Aminosalicylates
- JAK inhibitors
- Anti-integrin
- IL inhibitors
- Others
By Distribution Channel
- Hospital Pharmacy
- Drug Store and Retail Pharmacy
- Online Pharmacy
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- Pfizer Inc.
- UCB S.A.
- Johnson & Johnson Services, Inc.
- Novartis AG
- Bristol Myers Squibb
- ELI-LILLY
- Merck & Co. Inc.
- Celltrion Healthcare Co.,Ltd.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE
CHAPTER 5: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS
CHAPTER 6: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to the report, titled, “Inflammatory Bowel Disease Drugs Market," the inflammatory bowel disease drugs market size was valued at $21 billion in 2021, and is estimated to reach $34.5 billion by 2031, growing at a CAGR of 5.1% from 2022 to 2031.Inflammatory bowel disease is an idiopathic disease which is caused by dysregulated immune response of gastrointestinal tract. Ulcerative colitis is an inflammatory bowel disease that affects the colon and rectum of the human body. The disease affects people of any age and most commonly it begins during adolescence and early adulthood, but it may also occur later in life. Ulcerative colitis is highly prevalent in the U.S., England, and northern Europe. The most commonly preferred treatment options for ulcerative colitis are traditional medications made of biologics and small molecules. The Crohn’s disease is also the disorder which is related to gastrointestinal tract and these both ulcerative colitis and Crohn’s disease is collectively known as inflammatory bowel disease.
Factor that drives the growth of the global inflammatory bowel disease drugs market size include increase in number of patients with inflammatory bowel disease. In addition, rise in number of ulcerative colitis incidences propels the growth of the market. Furthermore, the Food and Drug Administration (FDA) aims to enhance availability of reliable and effective drugs to meet public health needs and increase access to treat consumers. In addition, the pharmaceutical sector has opened new approaches and collaborations in the industry to respond to the urgent needs of the pandemic. For instance, in addition, in June 2019, Abbvie completed the acquisition of Allergan to expand its product portfolio to offer extensively advanced treatments for patients. Allergan launched a monoclonal antibody called brazikumab, which is used in the treatment of ulcerative colitis. Thus, increase in development of new drugs drives the substantial growth of the market during forecast period. Thus, increase in number of partnerships and acquisitions among key players to expand its business in the area of treatment, is one of the prominent inflammatory bowel disease drugs market trends.
Furthermore, the presence of vast drug under pipeline for the treatment of inflammatory bowel disease is escalating the growth of the market. For instance, in October 2019, according to National Library of Medicine there were about 730 clinical trials being conducted on drug development related to inflammatory bowel disease in U.S, which is anticipated to foster the growth of the inflammatory bowel disease drugs market. In addition, according to Crohn’s and Colitis Foundation, around 25% of patients who suffer from Crohn’s disease in the U.S are prescribed with biologics. Also, there was high prevalence of Crohn’s disease in North America was about 319 per 100,000 population. These aforementioned factors increase the demand for inflammatory bowel disease drugs escalating the growth of the market.
Increase in government support for management of inflammatory bowel disease and surge in demand for effective prevention treatment are the major factors that drive the growth of the global inflammatory bowel disease drugs market. In addition, key players, such as AbbVie Inc., Takeda Pharmaceuticals, Pfizer Inc., and Bristol Myers Squibb contribute toward the market growth. However, high cost of drugs and limited reimbursement policies restricts the growth of the market. On the contrary, increase in number of drug manufacturing plants surge the demand for the treatment of inflammatory bowel disease drugs creating an opportunity for the manufacturers to tap and capitalize on the market.
The inflammatory bowel disease drugs market is studied across by type, drug class and distribution channel. On the basis of type, the market is segmented into ulcerative colitis and Crohn’s disease. By drug class, the market is fragmented into TNF inhibitors, Corticosteroids, Aminosalicylates, JAK inhibitors, Anti-integrin, IL inhibitors, and others. By distribution channel, it is categorized into hospital pharmacy, drug store & retail pharmacy and online pharmacy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By type, the Crohn’s disease segment dominated the global market in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to rise in prevalence of Crohn’s disease. In addition, the ulcerative colitis segment is expected to register higher CAGR during the forecast period owing to rise in cases of ulcerative colitis.
On the basis of drug class, the TNF inhibitor segment acquired the largest share of the inflammatory bowel disease drugs industry in 2021, and is expected to remain dominant throughout the forecast period. This is attributed to the increase in number of product approval.
By distribution channel drug store and retail pharmacy acquired the largest share in 2021, and is expected to remain dominant throughout the forecast period. This is attributed to the surge in demand for the drugs for the treatment of inflammatory bowel disease.
By region, the inflammatory bowel disease drugs industry is studied across North America, Europe, Asia-Pacific, and LAMEA. By Region, North America accounted for the largest inflammatory bowel disease drugs market share in 2021, and is expected to remain dominant throughout the forecast period. This was attributed to the presence of giant biopharmaceutical companies in the countries such as the U.S. In addition, increase in frequency of major pharmaceutical companies and their R&D activities drive the demand for therapeutic treatment in the region during the inflammatory bowel disease drugs market forecast.
Key Findings of the Study
- By type, the Crohn’s disease segment was the highest contributor according to the inflammatory bowel disease drugs market analysis in 2021.
- By drug class, the TNF inhibitor segment was the highest contributor to the market in 2021
- By distribution channel, the drug store & retail pharmacy segment dominate the growth of the market.
- North America accounted for a majority of the inflammatory bowel disease drugs market share in 2021, and is anticipated to remain dominant during the forecast period.
Companies Mentioned
- Takeda Pharmaceutical Company Limited
- Abbvie Inc.
- Pfizer Inc.
- Ucb S.A.
- Johnson & Johnson Services, Inc.
- Novartis AG
- Bristol Myers Squibb
- Eli-Lilly
- Merck & Co. Inc.
- Celltrion Healthcare Co.Ltd.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
